Skip to main content
Journal cover image

'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?

Publication ,  Journal Article
Gesty-Palmer, D; Luttrell, LM
Published in: Br J Pharmacol
September 2011

'Functional selectivity' refers to the ability of a ligand to activate and/or inhibit only a subset of the signals capable of emanating from its cognate G-protein-coupled receptor (GPCR). Whereas conventional GPCR agonism and antagonism can be viewed as modulating the quantity of efficacy, functionally selective or 'biased' ligands qualitatively change the nature of information flow across the plasma membrane, raising the prospect of drugs with improved therapeutic efficacy or reduced side effects. Nonetheless, there is little experimental evidence that biased ligands offer advantages over conventional agonists/antagonists in vivo. Recent work with the type I parathyroid hormone receptor (PTH(1) R) suggests that biased ligands that selectively activate G-protein-independent arrestin-mediated signalling pathways may hold promise in the treatment of osteoporosis. Parathyroid hormone (PTH) is a principle regulator of bone and calcium metabolism. In bone, PTH exerts complex effects; promoting new bone formation through direct actions on osteoblasts while simultaneously stimulating bone loss through indirect activation of osteoclastic bone resorption. Although the conventional PTH(1) R agonist teriparatide, PTH(1-34), is effective in the treatment of osteoporosis, its utility is limited by its bone-resorptive effects and propensity to promote hypercalcaemia/hypercalcuria. In contrast, d-Trp(12) ,Tyr(34) -bPTH(7-34) (PTH-βarr), an arrestin pathway-selective agonist for the PTH(1) R, induces anabolic bone formation independent of classic G-protein-coupled signalling mechanisms. Unlike PTH(1-34), PTH-βarr appears to 'uncouple' the anabolic effects of PTH(1) R activation from its catabolic and calcitropic effects. Such findings offer evidence that arrestin pathway-selective GPCR agonists can elicit potentially beneficial effects in vivo that cannot be achieved using conventional agonist or antagonist ligands.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Br J Pharmacol

DOI

EISSN

1476-5381

Publication Date

September 2011

Volume

164

Issue

1

Start / End Page

59 / 67

Location

England

Related Subject Headings

  • Receptor, Parathyroid Hormone, Type 1
  • Pharmacology & Pharmacy
  • Osteoporosis
  • Osteogenesis
  • Ligands
  • Humans
  • Bone and Bones
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gesty-Palmer, D., & Luttrell, L. M. (2011). 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol, 164(1), 59–67. https://doi.org/10.1111/j.1476-5381.2011.01450.x
Gesty-Palmer, Diane, and Louis M. Luttrell. “'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?Br J Pharmacol 164, no. 1 (September 2011): 59–67. https://doi.org/10.1111/j.1476-5381.2011.01450.x.
Gesty-Palmer D, Luttrell LM. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol. 2011 Sep;164(1):59–67.
Gesty-Palmer, Diane, and Louis M. Luttrell. “'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?Br J Pharmacol, vol. 164, no. 1, Sept. 2011, pp. 59–67. Pubmed, doi:10.1111/j.1476-5381.2011.01450.x.
Gesty-Palmer D, Luttrell LM. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol. 2011 Sep;164(1):59–67.
Journal cover image

Published In

Br J Pharmacol

DOI

EISSN

1476-5381

Publication Date

September 2011

Volume

164

Issue

1

Start / End Page

59 / 67

Location

England

Related Subject Headings

  • Receptor, Parathyroid Hormone, Type 1
  • Pharmacology & Pharmacy
  • Osteoporosis
  • Osteogenesis
  • Ligands
  • Humans
  • Bone and Bones
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences